GlaxoSmithKline

Pharma companies embrace branding

By

Big pharmaceutical companies are exploring "brand personality" in their marketing strategies, according to new research.

FDA approves Anoro Ellipta

The U.S. Food and Drug Administration have approved GlaxoSmithKline's Anoro™ Ellipta™, the company announced. The product is used to treat chronic obstructive pulmonary disease.

Glaxo will stop paying doctors for speaking gigs in industry-leading change

By

Pharmaceutical giant GlaxoSmithKline will stop paying healthcare professionals to speak about its products, and will alter other marketing and compensation practices that are common in the industry but derided by critics, the company announced Tuesday.

'Landmark' discovery brings a pill for Alzheimer's closer to reality, researchers say

By

The discovery of a compound that stops diseases like Alzheimer's and Parkinson's in their tracks is a "landmark" step toward a pill to treat these conditions, according to researchers in the United Kingdom.

Flu vaccines approved to ship

GlaxoSmithKline said it has received Food and Drug Administration approval to start shipping the 2013-2014 influenza virus vaccine to Centers for Disease Control and Prevention distribution centers and healthcare providers.

Avandia gets FDA win, but is unlikely to dominate market again

By

A Food and Drug Administration advisory panel has voted to ease measures that limit patient access to the diabetes pill Avandia. Many panelists, however, said precautions are still needed.

FDA approves highly anticipated COPD medication

By

The Food and Drug Administration has officially approved Breo Ellipta, a much-anticipated new treatment for chronic obstructive pulmonary disease.

Fraud investigations, audits bring dramatically rising 'savings,' OIG reports

By

The projected recoveries to the federal government from fraud-related audits and investigations are expected to rise 33% — or by $1.7 billion — in fiscal 2012, the Department of Health and Human Services Office of the Inspector General said this week.

GSK will pay $90 million to settle diabetes drug allegations

GlaxoSmithKline will pay a $90 million settlement to 38 states that claimed it unlawfully promoted its diabetes treatment Avandia (rosiglitazone). As a result of the settlement, GSK must change the way it promotes its diabetes drugs, including Avandia.

GSK agrees to pay $90 million to settle diabetes drug allegations

By

GlaxoSmithKline will pay a $90 million settlement to 38 states that claimed it unlawfully promoted its diabetes treatment Avandia (rosiglitazone). The attorneys general of several states confirmed the action on Thursday.

Don't miss any McKnight's news